Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Scinai Immunotherapeutics ( (SCNI) ) just unveiled an announcement.
On April 23, 2026, Scinai Immunotherapeutics Ltd. entered into a securities purchase agreement with institutional and accredited investors for a private placement of 5,208,333 American Depositary Shares at $0.48 per ADS, together with Series A and Series B warrants of equal size priced at $0.48 and $0.55 per ADS, respectively, and simultaneously structured the issuance with beneficial ownership limits to prevent any single holder exceeding specified ownership thresholds. In parallel, the company launched a warrant inducement with an existing institutional investor, lowering the exercise price of previously issued warrants and granting new five-year warrants, bringing combined gross proceeds from the private placement and inducement to approximately $2.61 million, expected to close on or about April 27, 2026, to fund expansion of its CDMO platform, advance customer programs, selectively invest in its immunotherapy pipeline, and support execution of its growth strategy while temporarily restricting additional equity and variable-rate issuances.
On April 23, 2026, Scinai also agreed to a registration rights arrangement requiring it to file a resale registration statement for the new securities within 15 days and seek SEC effectiveness within 60 to 90 days, aligning investor liquidity expectations with regulatory timelines. A.G.P./Alliance Global Partners served as exclusive financial advisor and warrant inducement agent, earning cash fees and additional warrants as compensation, underscoring continued capital-markets support for Scinai’s combined biopharma and CDMO business model despite the dilutive impact of discounted equity and warrant structures on existing shareholders.
Spark’s Take on SCNI Stock
According to Spark, TipRanks’ AI Analyst, SCNI is a Neutral.
The score is primarily held down by weak financial performance (ongoing losses, negative gross profit, and continued cash burn) despite an improved capital structure with much lower debt. Technicals also remain negative with the stock below major moving averages and a negative MACD. Valuation provides limited support because earnings are negative and no dividend yield is available.
To see Spark’s full report on SCNI stock, click here.
More about Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. is a Jerusalem-based biopharmaceutical company focused on developing innovative inflammation and immunology therapies, with a pipeline of candidates licensed from the Max Planck Society and PinCell S.r.l. The company also owns Scinai Biopharma Services Ltd., a contract development and manufacturing organization that provides development and manufacturing services to biotechnology and pharmaceutical clients, reflecting a dual focus on proprietary R&D and fee-for-service CDMO operations.
Average Trading Volume: 3,339,068
Technical Sentiment Signal: Sell
Current Market Cap: $2.56M
For a thorough assessment of SCNI stock, go to TipRanks’ Stock Analysis page.